Five-Year Analysis Shows Immunotherapy Plus Chemotherapy Before Lung Cancer Surgery Significantly Improves Long-Term Survival
Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — improved long-term survival overall compared with chemotherapy alone, according to a landmark study published June 2 in the New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology (ASCO), the world’s leading professional organization for physicians and oncology professionals caring for patients with cancer.
LEARN MORE
SEE ALL NEWS
Recent Posts
5 Healthy Habits That Help During Cancer Treatment
Understanding Mammogram Results
A 19-Year Fight Against Prostate Cancer Brings Man to Johns Hopkins Medicine
Scientists Advance Efforts to Create ‘Virtual Cell Lab’ As Testing Ground for Future Research with Live Cells
Ultra-Processed Foods: Q&A with 2 Dietitians
Radiation Therapy Overcomes Immunotherapy Resistance in Some Cancers
‘Power Surges’ on Cancer Cell Membranes May Fuel Progression of Disease
New Cancer Target Discovered
How surgeons build a new bladder for cancer patients like Deion Sanders